Abcuro, Inc.

Abcuro Inc.’s venture capital investors showed confidence in the ongoing Phase II/III MUSCLE clinical trial of ulviprubart (ABC008) in inclusion body myositis (IBM) by putting their support behind a $

Bain Capital Life Sciences (BCLS) raised its largest investment fund yet, nearly doubling the amount of money it has at its disposal to back both private and public drug developers, medical device and

Biopharmaceutical companies raised $3.95bn in venture capital globally during the third quarter of 2023, but firms raising small and large rounds brought in far less cash during the quarter compared t

Abcuro, Inc. has come a long way since it raised $42m in series A-1 venture capital at the start of 2021 and it plans to take its lead drug candidate even further with $155m in series B funding that